Skip to main content
PMC home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2021 Feb 18;12:628583. doi: 10.3389/fphar.2021.628583

Inhibition of 5-Lipoxygenase in Hepatic Stellate Cells Alleviates Liver Fibrosis

Shiyun Pu 1,2,†, Yanping Li 2,†, Qinhui Liu 2, Xu Zhang 3, Lei Chen 1,2, Rui Li 1,2, Jinhang Zhang 1,2, Tong Wu 1,2, Qin Tang 1,2, Xuping Yang 1,2, Zijing Zhang 1,2, Ya Huang 1,2, Jiangying Kuang 1,2, Hong Li 1,2, Min Zou 1, Wei Jiang 4, Jinhan He 1,2,*
PMCID: PMC7930623  PMID: 33679410

Abstract

Background and Purpose: Activation of hepatic stellate cells (HSC) is a central driver of liver fibrosis. 5-lipoxygenase (5-LO) is the key enzyme that catalyzes arachidonic acid into leukotrienes. In this study, we examined the role of 5-LO in HSC activation and liver fibrosis.

Main Methods: Culture medium was collected from quiescent and activated HSC for target metabolomics analysis. Exogenous leukotrienes were added to culture medium to explore their effect in activating HSC. Genetic ablation of 5-LO in mice was used to study its role in liver fibrosis induced by CCl4 and a methionine-choline-deficient (MCD) diet. Pharmacological inhibition of 5-LO in HSC was used to explore the effect of this enzyme in HSC activation and liver fibrosis.

Key Results: The secretion of LTB4 and LTC4 was increased in activated vs. quiescent HSC. LTB4 and LTC4 contributed to HSC activation by activating the extracellular signal-regulated protein kinase pathway. The expression of 5-LO was increased in activated HSC and fibrotic livers of mice. Ablation of 5-LO in primary HSC inhibited both mRNA and protein expression of fibrotic genes. In vivo, ablation of 5-LO markedly ameliorated the CCl4- and MCD diet-induced liver fibrosis and liver injury. Pharmacological inhibition of 5-LO in HSC by targeted delivery of the 5-LO inhibitor zileuton suppressed HSC activation and improved CCl4- and MCD diet-induced hepatic fibrosis and liver injury. Finally, we found increased 5-LO expression in patients with non-alcoholic steatohepatitis and liver fibrosis.

Conclusion: 5-LO may play a critical role in activating HSC; genetic ablation or pharmacological inhibition of 5-LO improved CCl4-and MCD diet-induced liver fibrosis.

Keywords: liver fibrosis, non-alcoholic steatohepatitis, α-SMA, ERK, zileuton

Introduction

Liver fibrosis is a common outcome of chronic liver injury such as chronic hepatotoxicity and non-alcoholic steatohepatitis (NASH) (Yu et al., 2018). If unmanaged, liver fibrosis can advance to cirrhosis and portal hypertension and often requires liver transplantation.

Hepatic stellate cells (HSC) play a key role in the formation of hepatic fibrosis (Higashi et al., 2017). In normal liver, HSC stay quiescent (Ogawa et al., 2007). With injurious stimuli, HSC transdifferentiate from a quiescent to activated state (Puche et al., 2013), becoming proliferative and producing a high amount of α-smooth muscle actin (α-SMA) and collagens (De Minicis et al., 2008). When this extracellular matrix accumulates excessively, it causes a fibrotic outcome and scars on the liver (Wu et al., 2018). The mechanism of HSC activation is not fully understood. Several signaling pathways participate in activating HSC (Woodhoo et al., 2012). Transforming growth factor-β (TGF-β) induces the phosphorylation of Smad2/3, which in turn promotes HSC activation and regulates the expression of fibrotic genes (Feng and Derynck, 2005). Activation of extracellular signal-regulated kinase (ERK) also contributes to HSC activation (Chen et al., 2016; Xie et al., 2017).

Arachidonic acid is the precursor of biologically and clinically important eicosanoids (Harizi et al., 2008). 5-lipoxygenase (5-LO) is the key enzyme that catalyzes arachidonic acid into leukotrienes (Alexander et al., 2011). Upon activation of 5-LO-activating protein (Flap), 5-LO oxidases arachidonic acid to the unstable intermediate 5-hydroperoxyeicosatetraenoic acid (5-HPETE), which is further dehydrated to form leukotriene A4 (LTA4) (Silverman and Drazen, 1999). LTA4 is converted to LTB4 via LTA4 hydrolase enzymes or to LTC4 via LTC4 synthase (Hofmann and Steinhilber, 2013). Both LTB4 and LTC4 are inflammatory lipid mediators that have important effects on the development of allergic rhinitis, bronchial asthma and atherosclerosis (Kowal et al., 2017). Inhibiting 5-LO by an inhibitor such as zileuton or blocking the effect of leukotrienes by their receptor antagonist such as montelukast, have been clinically used for asthma treatment (De Corso et al., 2019).

Recent studies indicated that the 5-LO pathway is associated with fibrosis (Qian et al., 2015; Su et al., 2016). 5-LO is expressed in human dermal fibroblasts, synovial fibroblasts, pulmonary fibroblasts and rat adventitial fibroblasts (Lin et al., 2014; Su et al., 2016). Activation of these cells can be restrained by 5-LO inhibitors (Lin et al., 2014; Su et al., 2016). LTB4 and LTC4 are secreted from lung fibroblasts (Shiratori et al., 1989; Paiva et al., 2010) and contribute to the proliferation and migration of these cells (Hirata et al., 2013). However, the role of 5-LO in HSC activation and liver fibrosis remains unknown.

In this study, we first used metabolomics to reveal that LTB4 and LTC4 are highly secreted during the activation of HSC. Secreted LTB4 and LTC4 promoted HSC activation via an ERK signaling pathway. Ablation or inhibition of 5-LO could suppress HSC activation. In mouse fibrotic models, ablation or targeted inhibition of 5-LO in HSC relieved liver fibrosis and injury. Finally, we found increased expression of 5-LO in liver sections of patients with NASH and fibrosis.

Materials and Methods

CCl4- and Methionine-Choline–Deficient Diet-Induced Models of Liver Fibrosis

For CCl4-induced liver fibrosis, 8-week-old C57 BL/6J (WT) and 5-lipoxygenase knockout (5-LO−/−) mice received an intraperitoneal (i.p.) injection of CCl4 (1 ml/kg body weight) twice a week. For MCD diet-induced liver fibrosis, WT and 5-LO−/− mice were fed a methionine-choline-supplied (MCS) or MCD diet (TROPHIC Animal Feed High-Tech, China) for 6 weeks. For therapeutic experiments, zileuton loaded in cRGDyK (Cyclo [Arg-Gly-Asp-DTyr-Lys])-guided liposome (RGD-Lip; 10 mg/kg) or vehicle was given by tail vein injection once every 3 days during the last 4 weeks of CCl4 or MCD diet treatment. All mice were housed at West China Hospital, Sichuan University in accordance with the guidelines of the animal care utilization committee of the institute. Food and water were freely available to mice, except otherwise stated.

Preparation and Characterization of RGD-Lips

Liposome (Lip) were prepared by the thin-film hydration method as described (Li et al., 2019; Zhang et al., 2020). Zileuton-loaded RGD-Lips (RGD-Lip/zileuton) were prepared by adding zileuton to the lipid organic solution before the solvent evaporation. The mean particle size and zeta potential of Lip were measured by dynamic light scattering with the Zetasizer Nano ZS90 instrument (Malvern, United Kingdom). The morphology of Lip was examined by transmission electron microscopy (H-600, Hitachi, Japan) with 2% phosphotungstic acid staining.

Serum Alanine Aminotransferase and Aspartate Aminotransferase Measurement

Serum ALT and AST levels were detected by using commercial kits (BioSino Bio-Technology and Science).

Hydroxyproline Assay

An amount of 50 mg liver tissue was dissolved in acid hydrolysate in glass tube and heated in boiling water bath for 20 min. Hydroxyproline was extracted according to the manufacturer's instructions and measured by using kits (Nanjing Jiancheng Bioengineering Institute).

Histology Analysis

The left lobe of the mouse liver was removed and immediately fixed in 10% neutral-buffered formalin, embedded in paraffin, and sectioned at 4 μm. Liver sections were stained with hematoxylin and eosin (H&E). For picrosirius red staining, liver sections were incubated with 0.1% sirius red in saturated picric acid for 60 min at room temperature. The Sirus Red positive area were detected by Image J. Fibrosis was assessed by picrosirius red staining according to the Ishak fibrosis criteria (Ishak et al., 1995).

Isolation and Culture of HSC

HSC were isolated from livers of WT mice and 5-LO−/− mice via in situ collagenase perfusion and underwent differential centrifugation on Optiprep (Sigma) density gradients, as described (Kwon et al., 2014). Isolated HSC were cultured in collagen-coated dishes with DMEM supplemented with 10% fetal bovine serum and antibiotics at 37°C. The purity of HSC was >95% as determined by their typical star-like shape and abundant lipid droplets.

Measurement of Zileuton Concentration in Different Types of Liver Cells

Mice were injected with CCl4 to cause liver fibrosis and treated with RGD-Lip/zileuton (10 mg/kg) for 4 h. Primary hepatocytes were isolated as described (Chen et al., 2019). The remaining cells were divided into three groups, fixed, perforated and stained with anti-α-SMA (HSC), anti-F4/80 (Kupffer cells) and anti-CD31 antibodies. HSC, Kupffer cells and LSECs were sorted by flow cytometry. Biliary epithelial cells were isolated as previously described (Li et al., 2019). Before extraction, cells were added to 30 μl ddH2O and underwent repeated freezing and thawing 5 times. A 25-μl aliquot of samples was added to a 1.5-ml polypropylene tube followed by 200 μl methanol. The mixture was vortex-mixed for 5 min and centrifuged at 14,000 rpm for 10 min at room temperature. The top layer was transferred to a new 1.5 ml polypropylene tube and evaporated to vacuum dryness at 37°C. Samples were re-dissolved with 50 μl 80% methanol. The mixture was vortex-mixed for 30 s and centrifuged at 14,000 rpm for 5 min at 4 °C. The 40-μl supernatant was transferred to a 250 μl polypropylene autosampler vial and sealed with a Teflon crimp cap. Partially purified cell samples were analyzed by using LC-MS/MS.

Systematic Metabolomic Analysis of Arachidonic Acid in 5-Lipoxygenase Pathway

Serum-free supernatant from primary mouse HSC were collected in an ice bath and extracted by solid-phase extraction. The metabolomics of arachidonic acid were detected and analyzed as described (Zhang et al., 2015).

LTB4 and LTC4 Measurement

Serum-free primary mouse HSC were collected in an ice bath and protected from light. Samples were centrifuged (600 × g, 5  min, 4°C), and with the resulting supernatant, LTB4 and LTC4 levels were determined by using ELISA kits (Cayman Chemical).

Immunofluorescence Staining

Primary HSC were fixed in 4% paraformaldehyde for 15 min, incubated in 0.2% Triton X-100 1×PBS for 15 min for permeabilization of cytomembrane. Antigens in paraffin sections were repaired by microwaving in 0.01 M citrate buffer (pH = 6.0) for 15 min. Both cells and tissue samples were incubated with antibodies in 4°C for 12 h. Immunoreactive compounds were incubated in room temperature for 1 h for conjugating with fluorescence-labeling secondary antibodies. All antibodies used in these experiments are in Supplementary Supplementary Table S1.

Western Blot Analysis

Western blot analysis was performed as described (Chen et al., 2019). The antibodies were listed in supplementary Supplementary Table S1. The expression of β-tubulin was a loading control. Immunoreactive bands were visualized on nitrocellulose membranes by using fluorescence-conjugated secondary antibodies (LI-COR, United States). The relative density was calculated by the ratio of the density of the protein of interest to β-tubulin.

Real-Time PCR Analyses

Total RNA isolation and PT-PCR was performed as described (Chen et al., 2019). The primers for detected genes are in Supplementary Table S2.

Statistical Analysis

Experiments were repeated at least 3 times with similar results. Quantitative results are expressed as the mean ± SEM. Statistical significance was determined by Student’s unpaired two-tailed t test or one-way ANOVA multiple comparison test as indicated in legends. p < 0.05 was considered statistically significant.

Results

LTB4 and LTC4 were Enriched in Supernatant of A-HSC

To explore the potential role of lipoxygenase pathway in arachidonic acid during HSC activation, we collected cell supernatants from quiescent HSC (q-HSC) and activated HSC (a-HSC, culture activated for 7 days) (Thi Thanh Hai et al., 2018). Among metabolites identified in the lipoxygenase pathway, target metabolomics revealed that LTB4 level was selectively increased in a-HSC (Supplementary Figure S1). ELISA further confirmed the increased LTB4 level in the supernatant of a-HSC (Figure 1A). Consistently, the level of LTC4, another metabolite of 5-LO, was also increased (Figure 1B).

FIGURE 1.

FIGURE 1

Open in a new tab

LTB4 and LTC4 levels were elevated during HSC activation and promote HSC activation. (A,B) Primary HSC were isolated from wild-type (WT) mice and cultured for 2 days (quiescent HSC [q-HSC]) or 7 days (activated HSC [a-HSC]). ELISA detection of secretion of LTB4 and LTC4 in supernatant from q-HSC or a-HSC. (C–G) Primary HSC were isolated from 5-LO−/− mice and cultured in DMEM with high glucose with 10% heat-inactivated fetal bovine serum for 2 days. Cells were co-cultured with vehicle (Veh), LTB4, or LTC4 for 4 days. (C,D) qRT-PCR analysis of mRNA levels of fibrotic genes. (E) Immunofluorescence analysis of effect of LTB4 or LTC4 treatment on α-SMA expression. (F,G) The protein level of α-SMA and Col1a1 protein. Data are mean ± SEM, n = 5, *p < 0.05, **p < 0.01.

LTB4 and LTC4 Contributed to Activating HSC via Phosphorylation of the ERK Pathway

The high level of LTB4 and LTC4 released by a-HSC prompted us to explore their function in activating HSC. To exclude the influence of endogenous LTB4 and LTC4, we isolated primary HSC from 5-LO−/− mice and added exogenous LTB4 or LTC4 to these cells for 4 days. Treatment with LTB4 or LTC4 significantly increased the expression of fibrotic genes including α-SMA, collagen 1a1 (Col1a1), Col3a1, Col5a1, tissue inhibitor of metalloproteinase 1 (Timp-1) and plasminogen activator inhibitor 1 (PAI-1) (Figures 1C,D). On immunofluorescence staining, LTB4 and LTC4 increased α-SMA accumulation in HSC as compared with controls (Figure 1E). Western blot analysis further confirmed that LTB4 and LTC4 elevated the protein levels of α-SMA and Col1a1 (Figures 1F,G). Therefore, LTB4 or LTC4 could promote HSC activation. We next explored the signaling pathway conveying the effect of LTB4 or LTC4. LTB4 or LTC4 seemed not to induce the phosphorylation of Smad2/3, a key pathway molecule for TGF-β-induced fibrosis (Supplementary Figure S2A). Instead, we found that LTB4 and LTC4 induced phosphorylation of the ERK1 signaling pathway (Figures 2A,B). The phosphorylation of ERK is necessary for LTB4- and LTC4-induced fibrosis because PD98059, a mitogen-activated protein kinase inhibitor, abolished their effects (Figures 2C,D; Supplementary Figure S2B). Other MAP kinases, according to p-p38 and p-JNK, were no change after LTB4 or LTC4 administration (Supplementary Figure S2C). Therefore, the effect of LTB4 and LTC4 on HSC may be mediated by ERK1 signaling.

FIGURE 2.

FIGURE 2

Open in a new tab

LTB4 and LTC4 promote HSC activation via ERK signaling pathway. (A,B) The protein levels of p-ERK, t-ERK and β-tubulin in HSC after treatment with LTB4, LTC4 or TGF-β1 for 30 min (C,D) Western blot analysis of protein levels of α-SMA and Col1a1 in primary HSC isolated from 5-LO−/− mice and pre-treated with PD98059 before administration of LTB4 or LTC4. Data are mean ± SEM, n = 5, *p < 0.05, **p < 0.01.

5-LO was Upregulated and Promoted HSC Activation

5-LO is the key enzyme in the synthesis of LTB4 and LTC4 (Alexander et al., 2011). We further investigated whether the high level of LTB4 and LTC4 released by a-HSC resulted from the increased expression of 5-LO. The mRNA and protein levels of 5-LO were significantly upregulated in a-HSC as compared with q-HSC (Figures 3A–C). In contrast, the expression of Flap was not changed by HSC activation (Figure 3B). In CCl4-induced liver fibrosis, 5-LO was also significantly increased along with other fibrotic genes (Figures 3D–F). Again, Flap expression was not significantly changed (Figure 3E). Liver fibrosis occurs during the progression of non-alcoholic steatohepatitis (NASH) (Nasr et al., 2018). Both the mRNA and protein levels of 5-LO were increased in an independent model of MCD diet-induced NASH (Anstee and Goldin, 2006) (Supplementary Figures S3A–C). These results suggest that increased 5-LO level may be responsible for the high level of LTB4 and LTC4 in a-HSC.

FIGURE 3.

FIGURE 3

Open in a new tab

5-LO was upregulated in a-HSC and fibrotic livers. The mRNA and protein levels of 5-LO detected in q-HSC and a-HSC (A–C) and with CCI4 treatment in mouse livers (D–F). The protein levels of Flap, Col1a1, α-SMA and β-tubulin were also detected in all above groups (B,E).

To further investigate the effect of 5-LO in HSC activation, we isolated primary HSC from wild-type and 5-LO−/− mice, then compared the expression of fibrotic genes after culture activation. Ablation of 5-LO significantly inhibited the expression of culture-induced fibrotic genes, such as α-SMA, Col1a1, Col3a1, Col5a1, Timp1 and PAI-1 (Figures 4A,B), indicating that 5-LO was involved in HSC activation. Inhibition of HSC activation was confirmed by immunofluorescent staining, which showed the expression of α-SMA less detectable in 5-LO−/− HSC (Figure 4C). Western blot analysis revealed that ablation of 5-LO suppressed α-SMA and Col1a1 expression (Figures 4D,E). The incubation of supernatant from WT a-HSC (WT-CM) was more effective to activate HSC than that from 5-LO−/− a-HSC (5-LO−/−-CM) (Supplementary Figures S4A,B).

FIGURE 4.

FIGURE 4

Open in a new tab

Genetic ablation of 5-LO restrained activation of primary HSC. Primary HSC were isolated from WT and 5-LO −/− mice. (A,B) qRT-PCR of mRNA levels of fibrosis genes. (C) Immunofluorescence analysis of effect of 5-LO ablation on α-SMA expression. (D,E) Western blot analysis of α-SMA and Col1a1 protein levels in q-HSC and a-HSC. Data are mean ± SEM, n = 5, *p < 0.05, **p < 0.01.

Genetic Ablation of 5-LO Ameliorated CCl4- and MCD Diet-Induced Liver Fibrosis, Inflammation and Hepatic Injury

To explore the in vivo function of 5-LO in liver fibrosis, we first exposed WT and 5-LO−/− mice to CCl4 twice a week for 8 weeks by intraperitoneal injection. As expected, CCl4 caused significant hepatic fibrosis as compared with olive oil, as assessed by picrosirius red staining (Figures 5A,B). In contrast, 5-LO−/− mice showed improved liver fibrosis and decreased hepatic fibrosis scores (Figure 5C). Consistently, the level of hydroxyproline was significantly lower in 5-LO−/− than WT mice (Figure 5D), which suggests that 5-LO deletion conferred resistance to CCl4-induced hepatic fibrosis. Among the fibrotic markers, α-SMA, collagens, TGF-β1, Timp-1/2 and PAI-1 were greatly suppressed in 5-LO−/− mice after CCl4 treatment (Figures 5E,F). The protein levels of α-SMA and Col1a1 were also greatly reduced in 5-LO−/− mice with chronic CCl4 injection (Figure 5G). CCl4 administration showed an increasing serum levels of ALT and AST (Supplementary Figure S5A). However, this liver injury was significantly decreased in 5-LO−/− mice. Chronic liver injury accelerated the accumulation of inflammatory cells around the vessels (Supplementary Figure S5B). Ablation of 5-LO greatly suppressed CCl4-induced inflammatory cell infiltration (Supplementary Figures S5B,C). These results were further supported by the decreased expression of inflammatory genes seen in the liver of 5-LO−/− mice (Supplementary Figure S5D).

FIGURE 5.

FIGURE 5

Open in a new tab

Genetic ablation of 5-LO ameliorated liver fibrosis after CCl4 injection. WT and 5-LO −/− mice were treated with olive oil or CCl4 for 8 weeks. Fibrosis stage was assessed by picrosirius red staining (A,B) for collagen according to the Ishak criteria (C). (D) Detection of hepatic hydroxyproline level. (E,F) qRT-PCR analysis of mRNA levels of fibrosis genes in livers of 4 groups. (G) Western blot analysis of the protein levels of α-SMA and Col1a1. Data are mean ± SEM, n = 7, *p < 0.05, **p < 0.01.

In another independent model of MCD diet-induced NASH, collagen deposition was reduced in livers of 5-LO−/− mice along with decreased fibrosis scores and hydroxyproline levels (Supplementary Figures S6A–D). Improved liver fibrosis was further confirmed by gene expression and protein analysis. Indeed, 5-LO ablation decreased the mRNA levels of fibrotic genes (α-SMA, Col1a1, Col3a1, Col5a1, TGF-β1, Timp-1/2 and PAI-1) (Supplementary Figures S6E,F) and the protein levels of α-SMA and Col1a1 (Supplementary Figures S6G,H). 5-LO ablation was protective in MCD-diet induced liver injury, as indicated by reduced serum levels of ALT and AST and inflammation scores (Supplementary Figures S7A–C). Inflammation plays an important role in MCD diet-induced NASH (Locatelli et al., 2014). Consistently, the mRNA levels of inflammatory genes including tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β) and monocyte chemoattractant protein 1 (Mcp-1) were decreased in 5-LO/− mice (Supplementary Figure S7D). The hepatic expression of CD68, a marker of macrophages, was also reduced (Supplementary Figure S7D). Therefore, 5-LO ablation ameliorated CCl4- and MCD diet-induced hepatic fibrosis, inflammation and liver injury.

Pharmacological Inhibition of 5-LO by Targeted Delivery Suppressed HSC Activation

The protective effect of 5-LO ablation prompted us to explore whether pharmacological inhibition of 5-LO would have a similar effect in restraining the activation of primary HSC. We used an HSC-specific drug delivery system by modifying sterically stable liposome (Lip) with cRGDyK, a pentapeptide that binds to integrin αvβ3 on the surface of a-HSC (Li et al., 2019). cRGDyK-guided Lip showed high selectivity toward activated but not quiescent HSC, and preferentially accumulated in the fibrotic liver (Li et al., 2019; Zhang et al., 2020). We loaded with zileuton, an inhibitor of 5-LO, into this delivery system (RGD-Lip/zileuton). The schematic illustration, particle size, morphology and entrapment efficiency were comparable to regular liposome (Supplementary Figures S8A,B, Supplementary Table S3). As expected, RGD-Lip/zileuton significantly suppressed the secretion of LTB4 by a-HSC (Supplementary Figure S9), which indicates the inhibition of 5-LO. In a-HSC, zileuton delivered by RGD-Lip greatly inhibited the expression of fibrotic genes including α-SMA, Col1a1, Col3a1, Col5a1, Timp-1 and PAI-1 (Figures 6A,B). These effects were further confirmed by immunofluorescent staining and western blot analysis (Figures 6C–E). Therefore, pharmacological inhibition of 5-LO suppressed HSC activation.

FIGURE 6.

FIGURE 6

Open in a new tab

Pharmacological inhibition of 5-LO suppressed activation of HSC. Primary HSC were isolated from WT mice and cultured in DMEM with high glucose and 10% heat-inactivated fetal bovine serum for 2 days (q-HSC) or 7 days (a-HSC). Primary HSC were treated with RGD-Lip or RGD-Lip/zileuton for 48 h (A,B) qRT-PCR analysis of effect of RGD-Lip/zileuton treatment on the mRNA expression of fibrotic genes. (C) Immunofluorescence analysis of effect of RGD-Lip/zileuton treatment on α-SMA expression. (D,E) Western blot analysis of α-SMA and Col1a1 protein levels in q-HSC and a-HSC. Data are mean ± SEM, n = 5, *p < 0.05, **p < 0.01.

Targeted Delivery of Zileuton to HSC Is Efficient Against Liver Fibrosis

We then evaluated the in vivo therapeutic effect of RGD-Lip/zileuton in CCl4-and MCD diet-induced liver fibrosis. In this experiment, mice were injected with CCl4 for 4 weeks, then treated with RGD-Lip/zileuton (10 mg/kg) every 3 days (Supplementary Figure S10A). RGD-Lip could specifically deliver zileuton to HSC because the concentration of zileuton in HSC was about 28.99-, 4.71-, 4.67- and 34.01-times higher than that in hepatocytes, Kupffer cells, endothelial cells and biliary epithelial cells, respectively (Supplementary Figure S10B). Specific inactivation of 5-LO by RGD-Lip/zileuton in HSC greatly decreased liver fibrosis as shown by picrosirius red staining and liver hydroxyproline quantification (Figures 7A–D). The expression of fibrotic genes such as α-SMA, Col1a1, Col3a1, Col5a1, Timp1 and PAI-1 was also mitigated (Figures 6E,F). Western blot analysis confirmed the reduced protein levels of Col1a1 and α-SMA (Figures 6G,H). Targeted inhibition of 5-LO in HSC also alleviated CCl4-induced liver injury and hepatic inflammation (Supplementary Figures S11A–C), but did not reduce the accumulation of F4/80 positive cells (Supplementary Figure S11D).

FIGURE 7.

FIGURE 7

Open in a new tab

Targeted delivery of zileuton to HSC is efficient against CCl4-induced liver fibrosis. WT mice were treated with olive oil or CCl4 for 8 weeks. During the last 4 weeks, mice given RGD-Lip or RGD-Lip/zileuton (10 mg/kg) every 3 days by tail vein injection. (A,B) Liver sections were collected for picrosirius red staining. (C) Fibrosis score was assessed for collagen according to the Ishak criteria. (D) Detection of hepatic hydroxyproline level. (E,F) qRT-PCR analysis of mRNA levels of fibrotic genes in livers of 4 groups. (G) Western blot analysis of the protein levels of α-SMA and Col1a1. Data are mean ± SEM, n = 7, *p < 0.05, **p < 0.01.

The therapeutic effects of RGD-Lip/zileuton were further demonstrated in an MCD diet-induced NASH model (Supplementary Figure S12). Specific inactivation of 5-LO in HSC explicitly alleviated MCD diet-induced liver fibrosis (Supplementary Figures S13A–D). Expression of fibrotic genes was suppressed in RGD-Lip/zileuton-treated mice (Supplementary Figures S13E,F) and α-SMA and collagen accumulation was reduced (Supplementary Figures S13G,H). Targeted delivery of zileuton also relieved liver injury in MCD-induced NASH (Supplementary Figure S14A). H&E staining and the expression of proinflammatory genes such as TNF-α and Mcp-1 indicated decreased inflammation in livers of RGD-Lip/zileuton-treated mice (Supplementary Figures S14B–D).

Increased Expression of 5-LO in Patients with Hepatic Fibrosis

We next determined whether 5-LO expression was changed in patients with NASH or liver fibrosis. The diagnosis of NASH and fibrosis was confirmed by H&E and picrosirius red staining (Supplementary Figures S15A–C). As compared with healthy individuals, the expression of 5-LO was increased in liver sections from patients with NASH and fibrosis (Figure 8). The expression of 5-LO was largely co-localized in α-SMA-positive cells, which were HSC (Figure 8). These results were consistent with 5-LO possibly having a positive role in activation of HSC in rodents.

FIGURE 8.

FIGURE 8

Open in a new tab

The expression of 5-LO was increased in liver sections of patients with fibrosis. Liver sections were collected from normal individuals or patients with non-alcoholic steatohepatitis or liver fibrosis and were stained with 5-LO and α-SMA. Data are mean ± SEM, n = 3.

Discussion

In this study, we found increased secretion of LTB4 and LTC4 in a-HSC. LTB4 and LTC4 contributed to HSC activation via ERK signaling. Elevated LTB4 and LTC4 was likely a result of increased expression of 5-LO during HSC activation. Genetic ablation of 5-LO protected mice against CCl4- and MCD diet-induced fibrosis and liver injury. Pharmacological inhibition of 5-LO in HSC by targeted delivery of zileuton prevented CCl4- and MCD diet-induced liver fibrosis. Finally, we found 5-LO level increased in liver sections of patients with liver fibrosis.

Several reports have suggested that 5-LO may play a role in fibrosis (Titos et al., 2004). 5-LO is expressed in various fibroblast cells, such as pulmonary fibroblasts, human myofibroblasts and skin fibroblasts (Nagy et al., 2011; Xiao et al., 2011) (Su et al., 2016). Titos et al. found 5-LO expressed in Kupffer cells (Titos et al., 2004). Pharmacological inhibition of 5-LO protected mice from CCl4-induced liver fibrosis (Horrillo et al., 2007). However, the following study could not confirm the expression of 5-LO in Kupffer cells (Takeda et al., 2017). Also, 5-LO expression was detected in HSC isolated from mice and rats (Paiva et al., 2010; Shajari et al., 2015). However, the function of 5-LO in HSC was not known. In our study, we found 5-LO expressed in HSC, and its expression was increased during their activation. With increased expression of 5-LO, the secretion of LTB4 and LTC4 was significantly elevated in a-HSC (Figures 1A,B; Supplementary Figure S1). LTB4 and LTC4 promoted HSC activation via ERK1 signaling pathway. This finding was consistent with a previous report of LTB4 and LTC4 leading to pulmonary fibrosis because of stimulating the activation and differentiation of fibroblasts (Hirata et al., 2013). Other lipoxygenases, such as 12-lipoxygenase, was also upregulated in a-HSC compared with q-HSC (Mori et al., 2020). However, we did not found the difference of 12-HETE, a metabolic of arachidonic acid through 12-lipoxygease, in q-HSC and a-HSC supernatant (Supplementary Figure S1). The role of 12-lipoxygenase in HSC deserves further study.

Liver fibrosis homeostasis is maintained by the balance of extracellular matrix synthetic machinery, contributing to increased rate of collagen synthesis and activities of the cellular fibrinolytic system. Timp-1 belongs to the Timp family and participates in degrading the extracellular matrix (Iredale, 2007). PAI-1 is a member of the serine protease inhibitor family, the main physiological inhibitor of serine protease, and contributes to the fibrinolytic system (Wang et al., 2007). Several studies have shown that Timp-1 and PAI-1 are key factors modulating fibrolysis and extracellular matrix deposition (Iredale, 2007; Wang et al., 2007). Knockout or pharmacological inhibition of Timp1 and PAI-1 inhibited fibrosis in liver (Parsons et al., 2004). Our in vitro results showed significantly increased expression of Timp-1 and PAI-1 in culture-activated HSC as compared with q-HSC. However, genetic ablation of 5-LO in HSC decreased levels of Timp1 and PAI-1, which may contribute to suppressed extracellular matrix deposition. In vivo, 5-LO ablation or pharmacological inhibition reduced the Timp-1 and PAI-1 expression, which helped reduce hydroxyproline level in mouse liver.

Oral treatment or injection of the 5-LO inhibitor zileuton causes systemic pharmacological side effects. Zileuton could increase oxidative stress in hepatocytes and may cause hepatocyte damage (Altumina, 1995). In addition, zileuton treatment was found to increase serum ALT and AST levels (Watkins et al., 2007). These results suggest that systemic zileuton administration may cause drug-induced side effects. cRGD is pentapeptide that binds with high affinity to integrin αV and β3 which are highly expressed in a-HSC (Li et al., 2019). It was also confirmed that cRGD-guided Lips specifically target activated HSC in vitro and vivo (Li et al., 2019; Zhang et al., 2020). In agreement with a previous report, we found that RGD-Lip-delivered zileuton was highly enriched in HSC but not hepatocytes, Kupffer cells, endothelial cells or biliary cells (Supplementary Figure S9B). RGD-Lip/zileuton administration significantly protected mice against CCl4-and MCD diet-induced liver fibrosis (Figure 7; Supplementary Figure S12). Therefore, targeted delivery of zileuton to inhibit 5-LO by RGD-Lip may be a promising way to manage liver fibrosis.

Obviously, both CCl4 and MCD-diet treatments induce inflammation, which were reduced by 5-LO ablation or RGD/Lip-zileuton administration. Horrillo et al. also found that 5-LO inhibitor protected mice from CCl4-induced liver inflammation (Horrillo et al., 2007). In our study, knockout of 5-LO did reduce the accumulation of F4/80 positive cells in fibrotic liver (Supplementary Figure S5C). However, treatment of RGD/Lip-zileuton did not reduce the accumulation of F4/80 positive cells (Supplementary Figure S11D). It was reported that activation of HSC mediated immune response (Chou et al., 2011; Chang et al., 2013; Bigorgne et al., 2016). We speculate that the beneficial effect of RGD/Lip-zileuton is more due to reduce in the HSC fibrosis compartment than reduced inflammation in the Kupffer cell compartment. The changes of these inflammatory indicators are related to the decrease of HSC activation.

LTB4 and LTC4 were reported as lipid mediators for attracting neutrophils and for lipid accumulation (Lund et al., 2017). Induction of LTB4 and LTC4 biosynthesis might cause hepatotoxicity via neutrophil activation (Shiratori et al., 1989; Takeda et al., 2017). 5-LO is the key enzyme that catalyzes arachidonic acid to form LTB4 and LTC4 (Alexander et al., 2011). In our study, both deletion of 5-LO and targeted inhibition of 5-LO in HSC protected mice against CCl4-and MCD diet-induced liver injury, at least in part by reducing LTB4 and LTC4 production in the liver.

In summary, we demonstrate that 5-LO inhibition confers resistance to CCl4- and MCD diet-induced hepatic fibrosis. The protective effect of 5-LO deletion was partially due to decreased level of LTB4 as well as LTC4 and reduced activation of HSC. Our data show that 5-LO is critical for liver fibrosis in the setting of supporting HSC activation. 5-LO expression was also increased in HSC in liver sections of patients with fibrosis. Strategies to target inhibition of 5-LO in HSC may be useful for treating liver fibrosis.

Acknowledgments

The authors thank Miss Huifang Li and Miss Ge Liang from Core Facility of West China Hospital for technical assistance.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics Statement

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and institutional requirements. The animal study was reviewed and approved by the Animal Care and Utilization Committee of West China Hospital.

Author Contributions

Participated in research design: SP, YL and JH. Conducted experiments: SP, YL, QL, XZ, LC, RL, JZ, TW, QT, XY, ZZ, YH, JK, and HL. Performed data analysis: MZ and WJ. Wrote or contributed to the writing of the manuscript: SP, YL, and JH.

Funding

This work was supported by the National Natural Science Foundation of China (81471068, 81603035 and 81870599), China Postdoctoral Fellowship (2018T110986), Young Scientist Fellowship of Sichuan University (2017SCU11026), Postdoctoral Fellowship of Sichuan University (2017SCU12036), and the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYJC18008).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.628583/full#supplementary-material.

Click here for additional data file. (17.3MB, pdf)

Abbreviations

ALT, alanine aminotransferase; AST, aspartate aminotransferase; 5-LO, 5-lipoxygenase; 5-HPETE, 5-hydroperoxyeicosatetraenoic acid; NASH, non-alcoholic steatohepatitis; MCD diet, methionine-choline-deficient diet; MCS diet, methionine-choline-supplied diet; CCl4, carbon tetrachloride; IL, interleukin; HSC, hepatic stellate cell; α-SMA, alpha smooth muscle actin; LTA4, leukotriene A4; LTB4, leukotriene B4; LTC4, leukotriene C4; TIMP-1/2, tissue inhibitor of metalloproteinase 1/2; TGF-β1, transforming growth factor-β1; PAI-1, plasminogen activator inhibitor 1; Flaps, 5-LO-activating proteins; ERK, extracellular signal-regulated protein kinase; MCP-1, monocyte chemoattractant protein 1; TNF-α, tumor necrosis factor alpha.

References

  1. Alexander S. P., Mathie A., Peters J. A. (2011). Guide to receptors and channels (GRAC), 5th edition. Br. J. Pharmacol. 164 (1), S1–S3. 10.1111/j.1476-5381.2011.01649_1.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Altumina M. M. (1995). Several characteristics of the pulmonary tuberculosis course in patients with different degree of diabetes mellitus compensation. Probl. Tuberk. 6,15–17. [PubMed] [Google Scholar]
  3. Anstee Q. M., Goldin R. D. (2006). Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87, 1–16. 10.1111/j.0959-9673.2006.00465.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bigorgne A. E., John B., Ebrahimkhani M. R., Shimizu-Albergine M., Campbell J. S., Crispe I. N. (2016). TLR4-Dependent secretion by hepatic stellate cells of the neutrophil-chemoattractant CXCL1 mediates liver response to gut microbiota. PLoS One 11, e0151063. 10.1371/journal.pone.0151063 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chang J., Hisamatsu T., Shimamura K., Yoneno K., Adachi M., Naruse H., et al. (2013). Activated hepatic stellate cells mediate the differentiation of macrophages. Hepatol. Res. 43, 658–669. 10.1111/j.1872-034X.2012.01111.x [DOI] [PubMed] [Google Scholar]
  6. Chen L., Liu Q., Tang Q., Kuang J., Li H., Pu S., et al. (2019). Hepatocyte-specific Sirt6 deficiency impairs ketogenesis. J. Biol. Chem. 294, 1579–1589. 10.1074/jbc.RA118.005309 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chen Q., Chen L., Kong D., Shao J., Wu L., Zheng S. (2016). Dihydroartemisinin alleviates bile duct ligation-induced liver fibrosis and hepatic stellate cell activation by interfering with the PDGF-βR/ERK signaling pathway. Int. Immunopharm. 34, 250–258. 10.1016/j.intimp.2016.03.011 [DOI] [PubMed] [Google Scholar]
  8. Chou H. S., Hsieh C. C., Yang H. R., Wang L., Arakawa Y., Brown K., et al. (2011). Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology 53, 1007–1019. 10.1002/hep.24162 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. De Corso E., Anzivino R., Galli J., Baroni S., Di Nardo W., De Vita C., et al. (2019). Antileukotrienes improve naso-ocular symptoms and biomarkers in patients with NARES and asthma. Laryngoscope 129, 551–557. 10.1002/lary.27576 [DOI] [PubMed] [Google Scholar]
  10. De Minicis S., Candelaresi C., Marzioni M., Saccomano S., Roskams T., Casini A., et al. (2008). Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo . Gut 57, 352–364. 10.1136/gut.2007.120303 [DOI] [PubMed] [Google Scholar]
  11. Feng X. H., Derynck R. (2005). Specificity and versatility in tgf-beta signaling through Smads. Annu. Rev. Cell Dev. Biol. 21, 659–693. 10.1146/annurev.cellbio.21.022404.142018 [DOI] [PubMed] [Google Scholar]
  12. Harizi H., Corcuff J. B., Gualde N. (2008). Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol. Med. 14, 461–469. 10.1016/j.molmed.2008.08.005 [DOI] [PubMed] [Google Scholar]
  13. Higashi T., Friedman S. L., Hoshida Y. (2017). Hepatic stellate cells as key target in liver fibrosis. Adv. Drug Deliv. Rev. 121, 27–42. 10.1016/j.addr.2017.05.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hirata H., Arima M., Fukushima Y., Sugiyama K., Tokuhisa T., Fukuda T. (2013). Leukotriene C4 aggravates bleomycin-induced pulmonary fibrosis in mice. Respirology 18, 674–681. 10.1111/resp.12072 [DOI] [PubMed] [Google Scholar]
  15. Hofmann B., Steinhilber D. (2013). 5-Lipoxygenase inhibitors: a review of recent patents (2010-2012). Expert Opin. Ther. Pat. 23, 895–909. 10.1517/13543776.2013.791678 [DOI] [PubMed] [Google Scholar]
  16. Horrillo R., Planagumà A., González-Périz A., Ferré N., Titos E., Miquel R., et al. (2007). Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor. J. Pharmacol. Exp. Therapeut. 323, 778–786. 10.1124/jpet.107.128264 [DOI] [PubMed] [Google Scholar]
  17. Iredale J. P. (2007). Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest. 117, 539–548. 10.1172/JCI30542 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. (1995). Histological grading and staging of chronic hepatitis. J. Hepatol. 22, 696–699. 10.1016/0168-8278(95)80226-6 [DOI] [PubMed] [Google Scholar]
  19. Kowal K., Gielicz A., Sanak M. (2017). The effect of allergen-induced bronchoconstriction on concentration of 5-oxo-ETE in exhaled breath condensate of house dust mite-allergic patients. Clin. Exp. Allergy 47, 1253–1262. 10.1111/cea.12990 [DOI] [PubMed] [Google Scholar]
  20. Kwon H. J., Won Y. S., Park O., Chang B., Duryee M. J., Thiele G. E., et al. (2014). Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice. Hepatology 60, 146–157. 10.1002/hep.27036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Li Y., Pu S., Liu Q., Li R., Zhang J., Wu T., et al. (2019). An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis. J. Contr. Release 303, 77–90. 10.1016/j.jconrel.2019.04.022 [DOI] [PubMed] [Google Scholar]
  22. Lin H. C., Lin T. H., Wu M. Y., Chiu Y. C., Tang C. H., Hour M. J., et al. (2014). 5-Lipoxygenase inhibitors attenuate TNF-α-induced inflammation in human synovial fibroblasts. PLoS One 9, e107890. 10.1371/journal.pone.0107890 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Locatelli I., Sutti S., Jindal A., Vacchiano M., Bozzola C., Reutelingsperger C., et al. (2014). Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice. Hepatology 60, 531–544. 10.1002/hep.27141 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lund S. J., Portillo A., Cavagnero K., Baum R. E., Naji L. H., Badrani J. H., et al. (2017). Leukotriene C4 potentiates IL-33-induced group 2 innate lymphoid cell activation and lung inflammation. J. Immunol. 199, 1096–1104. 10.4049/jimmunol.1601569 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mori Y., Kawakami Y., Kanzaki K., Otsuki A., Kimura Y., Kanji H., et al. (2020). Arachidonate 12S-lipoxygenase of platelet-type in hepatic stellate cells of methionine and choline-deficient diet-fed mice. J. Biochem. 168, 455–463. 10.1093/jb/mvaa062 [DOI] [PubMed] [Google Scholar]
  26. Nagy E., Andersson D. C., Caidahl K., Eriksson M. J., Eriksson P., Franco-Cereceda A., et al. (2011). Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts. Circulation 123, 1316–1325. 10.1161/CIRCULATIONAHA.110.966846 [DOI] [PubMed] [Google Scholar]
  27. Nasr P., Ignatova S., Kechagias S., Ekstedt M. (2018). Natural history of nonalcoholic fatty liver disease: a prospective follow-up study with serial biopsies. Hepatol. Commun. 2, 199–210. 10.1002/hep4.1134 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ogawa T., Tateno C., Asahina K., Fujii H., Kawada N., Obara M., et al. (2007). Identification of vitamin A-free cells in a stellate cell-enriched fraction of normal rat liver as myofibroblasts. Histochem. Cell Biol. 127, 161–174. 10.1007/s00418-006-0237-7 [DOI] [PubMed] [Google Scholar]
  29. Paiva L. A., Maya-Monteiro C. M., Bandeira-Melo C., Silva P. M., El-Cheikh M. C., Teodoro A. J., et al. (2010). Interplay of cysteinyl leukotrienes and TGF-β in the activation of hepatic stellate cells from Schistosoma mansoni granulomas. Biochim. Biophys. Acta. 1801, 1341–1348. 10.1016/j.bbalip.2010.08.014 [DOI] [PubMed] [Google Scholar]
  30. Parsons C. J., Bradford B. U., Pan C. Q., Cheung E., Schauer M., Knorr A., et al. (2004). Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 40, 1106–1115. 10.1002/hep.20425 [DOI] [PubMed] [Google Scholar]
  31. Puche J. E., Saiman Y., Friedman S. L. (2013). Hepatic stellate cells and liver fibrosis. Comp. Physiol. 3, 1473–1492. 10.1002/cphy.c120035 [DOI] [PubMed] [Google Scholar]
  32. Qian J., Tian W., Jiang X., Tamosiuniene R., Sung Y. K., Shuffle E. M., et al. (2015). Leukotriene B4 activates pulmonary artery adventitial fibroblasts in pulmonary hypertension. Hypertension 66, 1227–1239. 10.1161/HYPERTENSIONAHA.115.06370 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Shajari S., Laliena A., Heegsma J., Tuñón M. J., Moshage H., Faber K. N. (2015). Melatonin suppresses activation of hepatic stellate cells through RORα-mediated inhibition of 5-lipoxygenase. J. Pineal Res. 59, 391–401. 10.1111/jpi.12271 [DOI] [PubMed] [Google Scholar]
  34. Shiratori Y., Moriwaki H., Muto Y., Onishi H., Kato M., Asano F. (1989). Production of leukotriene B4 in parenchymal and sinusoidal cells of the liver in rats treated simultaneously with D-galactosamine and endotoxin. Gastroenterol. Jpn. 24, 640–645. 10.1007/BF02774162 [DOI] [PubMed] [Google Scholar]
  35. Silverman E. S., Drazen J. M. (1999). The biology of 5-lipoxygenase: function, structure, and regulatory mechanisms. Proc. Assoc. Am. Phys. 111, 525–536. 10.1046/j.1525-1381.1999.t01-1-99231.x [DOI] [PubMed] [Google Scholar]
  36. Su H. H., Lin H. T., Suen J. L., Sheu C. C., Yokoyama K. K., Huang S. K., et al. (2016). Aryl hydrocarbon receptor-ligand axis mediates pulmonary fibroblast migration and differentiation through increased arachidonic acid metabolism. Toxicology 370, 116–126. 10.1016/j.tox.2016.09.019 [DOI] [PubMed] [Google Scholar]
  37. Takeda T., Komiya Y., Koga T., Ishida T., Ishii Y., Kikuta Y., et al. (2017). Dioxin-induced increase in leukotriene B4 biosynthesis through the aryl hydrocarbon receptor and its relevance to hepatotoxicity owing to neutrophil infiltration. J. Biol. Chem. 292, 10586–10599. 10.1074/jbc.M116.764332 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Thi Thanh Hai N., Thuy L. T. T., Shiota A., Kadono C., Daikoku A., Hoang D. V., et al. (2018). Selective overexpression of cytoglobin in stellate cells attenuates thioacetamide-induced liver fibrosis in mice. Sci. Rep. 8, 17860. 10.1038/s41598-018-36215-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Titos E., Planagumà A., López-Parra M., Villamor N., Miquel R., Jiménez W., et al. (2004). 5-Lipoxygenase (5-LO) is involved in kupffer cell survival. Possible role of 5-LO products in the pathogenesis of liver fibrosis. Comp. Hepatol. 3 (1), S19. 10.1186/1476-5926-2-S1-S19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wang H., Zhang Y., Heuckeroth R. O. (2007). PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett. 581, 3098–3104. 10.1016/j.febslet.2007.05.049 [DOI] [PubMed] [Google Scholar]
  41. Watkins P. B., Dube L. M., Walton-Bowen K., Cameron C. M., Kasten L. E. (2007). Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug Saf. 30, 805–815. 10.2165/00002018-200730090-00006 [DOI] [PubMed] [Google Scholar]
  42. Woodhoo A., Iruarrizaga-Lejarreta M., Beraza N., García-Rodríguez J. L., Embade N., Fernández-Ramos D., et al. (2012). Human antigen R contributes to hepatic stellate cell activation and liver fibrosis. Hepatology 56, 1870–1882. 10.1002/hep.25828 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Wu X., Zhi F., Lun W., Deng Q., Zhang W. (2018). Baicalin inhibits PDGF-BB-induced hepatic stellate cell proliferation, apoptosis, invasion, migration and activation via the miR-3595/ACSL4 axis. Int. J. Mol. Med. 41, 1992–2002. 10.3892/ijmm.2018.3427 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Xiao R., Yoshida N., Higashi Y., Lu Q. J., Fukushige T., Kanzaki T., et al. (2011). Retinoic acids exhibit anti-fibrotic activity through the inhibition of 5-lipoxygenase expression in scleroderma fibroblasts. J. Dermatol. 38, 345–353. 10.1111/j.1346-8138.2010.00993.x [DOI] [PubMed] [Google Scholar]
  45. Xie Y. X., Liao R., Pan L., Du C. Y. (2017). ERK pathway activation contributes to the tumor-promoting effects of hepatic stellate cells in hepatocellular carcinoma. Immunol. Lett. 188, 116–123. 10.1016/j.imlet.2017.06.009 [DOI] [PubMed] [Google Scholar]
  46. Yu J., Hu Y., Gao Y., Li Q., Zeng Z., Li Y., et al. (2018). Kindlin-2 regulates hepatic stellate cells activation and liver fibrogenesis. Cell Death Dis. 4, 34. 10.1038/s41420-018-0095-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Zhang J., Li Y., Liu Q., Huang Y., Li R., Wu T., et al. (2020). Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on Smad2 in hepatic stellate cells. Hepatology. 10.1002/hep.31418 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Zhang X., Tan Z., Wang Y., Tang J., Jiang R., Hou J., et al. (2015). PTPRO-associated hepatic stellate cell activation plays a critical role in liver fibrosis. Cell. Physiol. Biochem. 35, 885–898. 10.1159/000369746 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (17.3MB, pdf)

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES